Riverwater Partners LLC Makes New $1.59 Million Investment in Integer Holdings Co. (NYSE:ITGR)

Riverwater Partners LLC purchased a new stake in Integer Holdings Co. (NYSE:ITGR - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 11,982 shares of the medical equipment provider's stock, valued at approximately $1,588,000.

Several other institutional investors have also recently made changes to their positions in the stock. Mather Group LLC. increased its position in Integer by 304.3% during the fourth quarter. Mather Group LLC. now owns 190 shares of the medical equipment provider's stock worth $25,000 after buying an additional 143 shares during the last quarter. Lee Danner & Bass Inc. bought a new stake in Integer in the 4th quarter valued at $27,000. R Squared Ltd acquired a new stake in Integer during the 4th quarter valued at $44,000. Versant Capital Management Inc increased its holdings in shares of Integer by 98.4% in the fourth quarter. Versant Capital Management Inc now owns 369 shares of the medical equipment provider's stock valued at $49,000 after purchasing an additional 183 shares during the last quarter. Finally, Principal Securities Inc. raised its position in shares of Integer by 31.2% in the fourth quarter. Principal Securities Inc. now owns 639 shares of the medical equipment provider's stock valued at $85,000 after purchasing an additional 152 shares during the period. Institutional investors and hedge funds own 99.29% of the company's stock.

Analysts Set New Price Targets

A number of research analysts recently commented on the stock. KeyCorp upped their price target on shares of Integer from $144.00 to $154.00 and gave the company an "overweight" rating in a research note on Friday, January 24th. Truist Financial lifted their price target on Integer from $147.00 to $163.00 and gave the stock a "buy" rating in a report on Wednesday, December 11th. Raymond James started coverage on Integer in a report on Friday, March 28th. They issued an "outperform" rating and a $145.00 price objective on the stock. Benchmark boosted their target price on shares of Integer from $140.00 to $150.00 and gave the company a "buy" rating in a research report on Friday, February 21st. Finally, Oppenheimer lowered shares of Integer from an "outperform" rating to a "market perform" rating in a research report on Friday, February 21st. Two research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat.com, Integer presently has an average rating of "Moderate Buy" and an average price target of $148.56.

Remove Ads

Integer Price Performance

Shares of ITGR stock traded down $2.92 on Thursday, hitting $113.45. 240,681 shares of the company's stock were exchanged, compared to its average volume of 338,401. The stock has a market cap of $3.81 billion, a P/E ratio of 33.58, a price-to-earnings-growth ratio of 1.72 and a beta of 1.09. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.95 and a quick ratio of 2.09. The company has a 50 day moving average of $124.83 and a 200 day moving average of $131.10. Integer Holdings Co. has a 12 month low of $104.93 and a 12 month high of $146.36.

Integer (NYSE:ITGR - Get Free Report) last announced its quarterly earnings results on Thursday, February 20th. The medical equipment provider reported $1.43 EPS for the quarter, missing analysts' consensus estimates of $1.46 by ($0.03). The firm had revenue of $449.50 million during the quarter, compared to the consensus estimate of $446.28 million. Integer had a net margin of 6.92% and a return on equity of 11.65%. On average, equities research analysts predict that Integer Holdings Co. will post 6.01 EPS for the current year.

Integer Company Profile

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.